Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

Overview of attention for article published in Lancet Neurology, December 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

news: 2 news outlets
blogs: 1 blog
policy: 1 policy source

twitter: 20 X users
patent: 2 patents
guideline: 2 clinical guideline sources

Readers on

mendeley: 159 Mendeley

So far, Altmetric has seen 20 X posts from 20 X users, with an upper bound of 47,163 followers.

Discussing outcomes of the COMET study looking at efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease https://t.co/LHlmClNSsM https://t.co/n8SNwJmNfI

【抄読会】 https://t.co/w0cS0cuV7u avalglucosidase alfa の第3相多施設ランダマイズ化試験を、遅発型ポンペ病患者を対象として行いalglucosidase alfaに対する非劣性を確認した。

RT @neurochecklists: Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET…

Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial https://t.co/Z2PBFkuk8W

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 16 additional X posts.